source
- Silence Therapeutics moves siRNA drug for polycythemia vera to Phase 3 after Phase 2 successSilence Therapeutics announced that its siRNA candidate divesiran achieved its primary endpoint in a Phase 2 study in patients with polycythemia vera, a rare blood cancer. The trial results showed…
- Victory Medical Center Pharmacy recalls glutathione vials over high endotoxin levelsVictory Medical Center Pharmacy in Austin announced a voluntary recall of specific lots of its compounded glutathione 200 mg/mL multi‑dose vials. Testing at the pharmacy detected elevated bacteria…